Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

In situ cancer vaccination refers to any approach that exploits tumour antigens available at a
tumour site to induce tumour-specific adaptive immune responses. These approaches hold …

Simple Summary Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is the first
oncolytic viral immunotherapy to be approved for the local treatment of unresectable …

Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer,
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …

To effectively build on the recent successes of immune checkpoint blockade, adoptive T cell
therapy and cancer vaccines, it is critical to rationally design combination strategies that will …

Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill
infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells …

Oncolytic viruses (OVs) are novel immunotherapeutic agents whose anticancer effects come
from both oncolysis and elicited antitumor immunity. OVs induce mostly immunogenic …

Melanoma often spreads to cutaneous or subcutaneous sites that are amenable to direct,
intralesional injection. As such, develo** effective injectable agents has been of …

Abstract In this White Paper, we discuss the current state of microbial cancer therapy. This
paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National …

Oncolytic vaccinia virus (VV) therapy has shown promise in preclinical models and in clinical
studies. However, complete responses have rarely been observed. This lack of efficacy is …